As of 14:27:33 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

The markets are selling off once again today fueled by recession fears owing to tariff fallout. After what proved to be the ...

Vertex's success since the early 2010s is due to its work in CF. The company famously markets the only approved medicines that target the underlying causes of this condition. Thanks to its monopoly, ...

Jones Financial Companies Lllp increased its stake in Vertex Pharmaceuticals by 75.5% in Q4, now holding 2,468 shares valued ...

Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

The stock's fall snapped a four-day winning streak.

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...